Clinical Trial Update: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating adjuvant ribociclib with endocrine therapy in high-risk HR+/HER2- early breast cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-01-15